How much funding has Lutris Pharma raised?

Lutris Pharma has raised $30.0M in total funding, most recently a Series A round.

Who are Lutris Pharma's investors?

Lutris Pharma's investors include Pontifax, Columbus Venture Partners, Peregrine Ventures, aMoon.

When was Lutris Pharma founded?

Lutris Pharma was founded in 2016.

Where is Lutris Pharma headquartered?

Lutris Pharma is headquartered in Tel Aviv, Israel.

What industry is Lutris Pharma in?

Lutris Pharma operates in Biotech.

How many employees does Lutris Pharma have?

Lutris Pharma has 1-10 employees.

Lutris Pharma

Tel Aviv, Israel · Founded 2016 · $30.0M raised

Biotech

Headquarters: Tel Aviv
Employees: 1–10
Founded: 2016
Business Model: B2B

Website: lutris-pharma.com
Total Funding: $30.0M
Last Round: $30.0M Series AJan 2025
Rounds: 2

About

Lutris Pharma is a Tel Aviv-based clinical-stage biopharmaceutical company focused on improving the effectiveness and tolerability of anti-cancer therapies. The company develops proprietary treatments designed to reduce the dermatological side effects — such as skin toxicity — that commonly limit dosing and quality of life for oncology patients receiving targeted cancer therapies. Lutris raised $30 million in financing to advance its lead biopharmaceutical program through clinical development.

Summary

Lutris Pharma is a Biotech company based in Tel Aviv, Israel, founded in 2016. It has raised $30.0M in total across 2 rounds, most recently a $30.0M Series A round in Jan 2025. Investors include Pontifax, Columbus Venture Partners and Peregrine Ventures.